[go: up one dir, main page]

WO2009025149A1 - Adnf receptor - Google Patents

Adnf receptor Download PDF

Info

Publication number
WO2009025149A1
WO2009025149A1 PCT/JP2008/063428 JP2008063428W WO2009025149A1 WO 2009025149 A1 WO2009025149 A1 WO 2009025149A1 JP 2008063428 W JP2008063428 W JP 2008063428W WO 2009025149 A1 WO2009025149 A1 WO 2009025149A1
Authority
WO
WIPO (PCT)
Prior art keywords
adnf
amino acid
receptor
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/063428
Other languages
French (fr)
Japanese (ja)
Inventor
Masaaki Matsuoka
Sadakazu Aiso
Tomo Nishimoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keio University
Original Assignee
Keio University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Keio University filed Critical Keio University
Publication of WO2009025149A1 publication Critical patent/WO2009025149A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)

Abstract

The object is to identify a receptor for ADNF to elucidate a specific signaling pathway of the anti-ALS activity of ADNF, and to provide a screening system for identifying a compound capable of binding to the ADNF receptor or a compound capable of inhibiting or enhancing the binding between ADNF and the ADNF receptor or the like. Disclosed is an ADNF receptor comprising a polypeptide having any one of the following amino acid sequences (1) to (3): (1) the amino acid sequence depicted in SEQ ID NO:2 or 3; (2) an amino acid sequence having the deletion, substitution or insertion of one or several amino acid residues in the amino acid sequence depicted in SEQ ID NO:2 or 3; and (3) an amino acid sequence having a 70% or more homology with the amino acid sequence depicted in SEQ ID NO:2 or 3.
PCT/JP2008/063428 2007-08-23 2008-07-25 Adnf receptor Ceased WO2009025149A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-216664 2007-08-23
JP2007216664A JP2009046459A (en) 2007-08-23 2007-08-23 ADNF receptor

Publications (1)

Publication Number Publication Date
WO2009025149A1 true WO2009025149A1 (en) 2009-02-26

Family

ID=40378057

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/063428 Ceased WO2009025149A1 (en) 2007-08-23 2008-07-25 Adnf receptor

Country Status (2)

Country Link
JP (1) JP2009046459A (en)
WO (1) WO2009025149A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014025761A1 (en) * 2012-08-07 2014-02-13 Children's Medical Center Corporation Methods to treat neurodegenerative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097156A1 (en) * 2004-04-08 2005-10-20 Nishimoto, Tomo Remedy for neurodegenerative diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005097156A1 (en) * 2004-04-08 2005-10-20 Nishimoto, Tomo Remedy for neurodegenerative diseases
WO2005099741A1 (en) * 2004-04-08 2005-10-27 Noevir Co., Ltd. Remedy for motoneuron diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BAUER H. ET AL.: "Characterization of p40/GPR69A as a peripheral membrane protein related to the lantibiotic synthetase component C", BIOCHEM.BIOPHYS.RES.COMMUN., vol. 275, 2000, pages 69 - 74 *
BLISNICK T. ET AL.: "LANCL1, an erythrocyte protein recruited to the Maurer's clefts during plasmodium falciparum development", BIOCHEM.PARASITOL., vol. 141, 2005, pages 39 - 47 *
BRENNEMAN D.E. ET AL.: "Activity-dependant neurotrophic factor:structure-activity relationships of femtomolar-acting peptides", J.PHARMACOL.EXP.THER., vol. 285, no. 2, 1998, pages 619 - 627 *
CHIBA T. ET AL.: "Neuroprotective effect of activity-dependent neurotrophic factor against toxicity from familial amyotrophic lateral sclerosis-linked mutant SOD1 in vitro and in vivo", J.NEUROSCI.RES., vol. 78, 2004, pages 542 - 552 *
CHUNG C.H.Y. ET AL.: "Identification of lanthionine synthase c-like protein-1 as a prominent glutathione binding protein expressed in the mammalian central nervous system", BIOCHEMISTRY, vol. 46, February 2007 (2007-02-01), pages 3262 - 3269 *
MAYER H. ET AL.: "Characterization of rat LANCL1, a novel member of the lanthionine synthase c-like protein family,highly expressed in testis and brain", GENE, vol. 269, 2001, pages 73 - 80 *

Also Published As

Publication number Publication date
JP2009046459A (en) 2009-03-05

Similar Documents

Publication Publication Date Title
NZ591855A (en) Novel immunotherapy against several tumors including neuronal and brain tumors
WO2008086086A3 (en) Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
NZ602170A (en) Modified leptin polypeptides and their uses
NZ609216A (en) Anticancer fusion protein
DK2162462T3 (en) CXC-CHEMOKIN RECEPTOR-4 (CXCR4) ANTAGONISTIC POLYPEPTIDE
WO2009025117A1 (en) Cdca1 peptide and pharmaceutical agent comprising the same
MX2009008270A (en) Novel polypeptide having anti-tumor activity.
WO2009047992A1 (en) Udp-glucuronyl transferase and polynucleotide encoding the same
MX2008009493A (en) Novel peptide and use thereof.
BR112012006579A2 (en) npr-b agonists.
WO2014037565A3 (en) Inhibiting peptides derived from triggering receptor expressed on myeloid cells-1 (trem-1) trem-like transcript 1 (tlt-1) and uses thereof
WO2008113536A8 (en) Neurotrophic peptides
WO2007089038A8 (en) Novel phospholipase d
WO2005087811A3 (en) Estrogen receptors and methods of use
CY1111630T1 (en) CYCLING PRODUCERS
MX2010010213A (en) Partial peptide of lacritin.
NZ707637A (en) Signal biomarkers
NZ589365A (en) Peptidyl diacylglycerides
WO2006135793A3 (en) Protein engineering with analogous contact environments
WO2009025149A1 (en) Adnf receptor
WO2014162007A3 (en) Thymic stromal lymphopoietin fragments and uses thereof
WO2007029262A3 (en) Compositions and methods using same for the detection of viruses
NZ591133A (en) Novel melanoma antigen peptide and uses thereof
WO2003021262A1 (en) Screening method
MY160224A (en) Signal peptide contained in mannose-specific lectin precursor, nucleic acid encoding the signal peptide, and use of the signal peptide and the nucleic acid

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08791672

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08791672

Country of ref document: EP

Kind code of ref document: A1